|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 7 (October 1), 1997:
pp. 2644-2653
Thrombin Cleavage-Independent Deposition of Fibrinogen in Extracellular Matrices
By
Gayle Guadiz,
Lee Ann Sporn, and
Patricia J. Simpson-Haidaris
From the Departments of Medicine, Microbiology and Immunology, and Pathology, University of Rochester School of Medicine and Dentistry, Rochester, NY.
 |
ABSTRACT |
Lung epithelial cells (A549) synthesize and secrete fibrinogen (FBG) in vitro when stimulated with interleukin-6 and dexamethasone. This FBG secretion is polarized in the basolateral direction, suggesting that FBG is a component of the extracellular matrix (ECM). Immunofluorescent staining of A549 cells showed a fibrillar pattern of FBG, similar to the staining detected using antibodies against the matrix constituents, collagen type IV and fibronectin (FN). The same pattern of staining was detected using antibodies against fibrinopeptides A and B, as well as with the T2G1 monoclonal antibody against the fibrin-specific epitope,  15-21. Matrix staining was unaltered in the presence of the thrombin inhibitor, hirudin, or the plasmin inhibitor, aprotinin, consistent with the interpretation that matrix deposition of FBG does not require such enzymatic action. Metabolic labeling studies confirmed that FBG secreted from A549 cells or deposited into the ECM showed no evidence of thrombin or plasmin proteolytic processing or of transglutaminase-mediated covalent cross-linking ( - dimers or  -polymers). Incubation of either A549 cell-derived or purified plasma FBG with cultures of human foreskin fibroblasts resulted in FBG deposition in the ECM that colocalized with matrix fibrils containing endogenously produced FN and laminin (LN). Binding of FBG to this exogenously produced matrix was unaltered by inhibition of thrombin and plasmin action, yet also exhibited exposure of the fibrin-specific epitope, 15-21. The majority (~70%) of newly synthesized and secreted FBG is bound to the cell surface as determined by its trypsin-sensitivity. Cell surface-bound FBG is initially deoxycholate-soluble, which, over time, becomes incorporated in the deoxycholate-insoluble ECM in a similar fashion to FN. These data suggest that matrix incorporation requires the binding of secreted FBG to cell-associated matrix assembly sites. However, unlike FN, FBG in the ECM is composed of the dimeric protamer (A/B/) and not high molecular weight polymers indicative of fibrin. This study provides evidence that deposition of FBG in both endogenous and exogenously produced matrices results in conformational changes that occur independently of thrombin cleavage. This matrix-bound FBG, on which unique cell-reactive domains are likely exposed, could augment cellular response mechanisms evoked during injury and inflammation.
| |
INTRODUCTION |
TISSUE INJURY INDUCES an inflammatory response that results in upregulation of hepatic fibrinogen (FBG) synthesis and its secretion along with other acute-phase reactants.1 Cutaneous or vascular injury activates blood coagulation, resulting in thrombin-mediated conversion of FBG to fibrin via the enzymatic release of fibrinopeptides A and B (FPA and FPB).2-4 The resulting fibrin provisional matrix facilitates platelet adherence, angiogenesis, cell migration, and cell spreading.5-10 Although the liver is the primary source of plasma FBG, several studies have shown a basal, constitutive expression of the FBG chain in extrahepatic tissues.11-13 Epithelial cells from intestine and cervix have been shown to synthesize fully assembled FBG in vitro.14,15 Cultured lung epithelial cells (A549) synthesize and secrete FBG after stimulation with interleukin-6 (IL-6) and dexamethasone (DEX),16 factors present during the acute-phase response.3 Furthermore, when A549 cells are cultured on polycarbonate filters, FBG secretion is polarized, with greater than 80% directed basolaterally.17 These findings suggest that FBG may be targeted to the basement membrane when synthesized in vivo.
Several proteins, including fibronectin (FN), thrombospondin, vitronectin, von Willebrand factor, and fibulin,18-23 function in both plasma and as components of basement membranes. Whereas plasma FBG has been well-characterized for its role in hemostasis, FBG has not heretofore been recognized as a component of extracellular matrices. This study examines the extracellular destination and structure of FBG. The results indicate that (1) nascent secreted FBG binds to the cell surface, (2) lung epithelial cells incorporate newly synthesized FBG into the extracellular matrix (ECM), (3) secreted FBG binds to exogenously produced matrix, and (4) upon its deposition in the matrix, FBG displays an epitope characteristic of fibrin. In that there is no evidence of thrombin or plasmin enzymatic action, it appears that surface-bound FBG undergoes a conformational change exposing a fibrin-like epitope. Furthermore, these results suggest that matrix-bound FBG may influence cell behavior in the context of wound repair and inflammation.
| |
MATERIALS AND METHODS |
Cells and culture conditions.
A549 human lung epithelial cells (CCL 185) and human foreskin fibroblasts (HFF )24 were grown to confluent monolayers in Kaighn's Nutrient Mixture F12 medium (Irvine Scientific Co, Santa Ana, CA) with 10% fetal bovine serum (FBS; Intergen, Purchase, NY).16 All cell culture reagents were obtained from Life Technologies (Gaithersburg, MD). A549 and HFF were seeded onto T-25 cm2 flasks, 6-well plates (Costar, Cambridge, MA), or 3.0-mm glass coverslips (Electron Microscopy Sciences, Fort Washington, PA). For induction of FBG synthesis, cells were stimulated with IL-6 (25 U/mL) and DEX (0.1 µmol/L).16 For studies involving thrombin or plasmin inhibition, hirudin (1 U/mL; Sigma, St Louis, MO) and aprotinin (200 KIU/mL; Miles, Kankakee, IL), respectively, were added to culture media. Human thrombin (CalBiochem, La Jolla, Ca) was used at 1.0 U/mL and plasmin was used at at 0.25 U/mL.
Immunofluorescent staining.
Immunofluorescent labeling of cells cultured on glass coverslips was performed.17 After treatment with DEX + IL-6, cells were washed twice with 1 mL phosphate-buffered saline, fixed in 3.7% formaldehyde, permeabilized with 0.5% Triton X-100 when required, and stained with 10 µg/mL primary antibody as listed in Table 1. Monoclonal antibody (MoAb) raised against chicken -tubulin, which also recognizes human -tubulin, was obtained from Amersham (Arlington Heights, IL). Rhodamine- and fluorescein-conjugated antibodies to rabbit or mouse Igs (Cappel, West Chester, PA) were used as secondary antibodies.
Iodination, metabolic labeling, and immunoprecipitation.
Purified human FBG (CalBiochem) was depleted of FN by gelatin-Sepharose chromatography and radioiodinated.17 For studies analyzing 125I-FBG deposition in matrix, 2, 10, or 50 µg/mL of 125I-labeled FBG was added to HFF cultured in T-25 cm2 flasks and incubated at 37°C for 72 hours. The washed cell monolayers were fixed and then stained by indirect immunofluorescence as described above. For controlled experiments analyzing thrombin activity, 10 µg/mL 125I-FBG was used per 1 mL of reaction. Metabolic labeling of cellular proteins was performed with 35S-cys + 35S-met Express Protein Labeling Mix (Dupont-NEN, Boston, MA). Unless otherwise specified, cells were lysed in standard cell lysing buffer consisting of 0.5% deoxycholate (DOC), 0.5% nonidet P-40, 0.1% sodium dodecyl sulfate (SDS), 1 mmol/L N-ethylmaleimide (NEM), 1 mmol/L iodoacetic acid (IAA), 2 mmol/L phenylmethylsulfonyl fluoride (PMSF ), 2 mmol/L EDTA in 0.1 mol/L Tris-HCl, pH 8.3. Labeled FBG was immunoprecipitated from culture media or cell lysate using purified rabbit antihuman FBG IgG coupled to protein A-Sepharose (Sigma).16 After immunoprecipitation, samples were analyzed by electrophoresis on Laemmli or Weber Osborn polyacrylamide-SDS gels30 or 2% agarose-SDS gels.16
Analysis of cell/matrix-associated FBG.
To determine whether cell/matrix-associated FBG is intracellular, bound to cells, and/or incorporated into the ECM, confluent cultures of A549 cells were induced for 18 hours with DEX + IL-6 and then metabolically labeled (100 µCi/mL) for up to 120 minutes. At the end of each time point, media were saved and the cells were washed twice with 1 mL Hank's Balanced Salt Solution. Control cells were scraped and lysed immediately in standard lysing buffer; trypsinized cells were lifted with 1 mL trypsin:EDTA (0.05%:0.53 mmol/L) by incubation for 5 minutes at 37°C. Trypsin action was stopped with soybean trypsin inhibitor at 500 µg/mL.31
Analysis of detergent-insoluble FBG.
To determine whether cell/matrix-associated FBG is a component of the DOC-insoluble fraction of the A549 ECM, cells were treated with DEX + IL-6 for 18 hours, pulse-labeled with 1 mCi/mL 35S-cys + met for 10 minutes, and chased with unlabeled complete medium for 2, 6, and 24 hours. At the end of the chase period, the culture medium was removed and the cell monolayers were washed three times in phosphate-buffered saline. The cells were scraped and lysed in 2% DOC in 20 mmol/L Tris-HCl, pH 8.8, containing 2 mmol/L each of PMSF, EDTA, IAA, and NEM. The DOC-insoluble fraction was recovered by centrifugation, and the pellet was washed and then solubilized in 1% SDS in 20 mmol/L Tris-HCl, pH 8.8, with 2 mmol/L each of PMSF, EDTA, IAA, and NEM.31,32 FBG was immunopurified and analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) after reduction on 6% polyacrylamide gels or without reduction on 2% agarose gels. Scanning densitometry was performed using the NIH Image 1.59 software and a ScanJet IIcx (Hewlitt Packard, Palo Alto, CA).
| |
RESULTS |
FBG synthesized by A549 lung epithelial cells is deposited into the ECM.
A549 cells were cultured to confluence on glass coverslips and then treated for 18 hours with IL-6 + DEX to induce FBG expression. Immunofluorescent staining was then performed using antibodies specific for the matrix constituents FN and collagen type IV, in parallel with an MoAb that recognizes fibrin(ogen) chain residues 63 through 78.25 Immunostaining for FN and collagen type IV on both untreated (not shown) and IL-6 + DEX-treated cells showed the presence of an extensive fibrillar ECM beneath and between cells (Fig 1C and 1D). Immunostaining using the FBG-specific MoAb J88B resulted in the appearance of a similar fibrillar pattern, which was present in IL-6 + DEX-treated cells (Fig 1B), but absent in unstimulated cells (Fig 1A). This result is consistent with the prior observation that unstimulated A549 cells express negligible quantities of FBG.16
View larger version (83K):
[in this window]
[in a new window]
| Fig 1.
Immunofluorescent detection of FBG in lung epithelial cell ECM. A549 cells grown on glass coverslips were treated with IL-6 and DEX for 18 hours (B through D) or untreated (A), fixed, and then stained with the following antibodies: (A and B) MoAb J88B for FBG; (C) PoAb for FN; and (D) MoAb COL-94 for collagen type IV. The bar in (D) represents 10 µm.
|
|
FBG deposition in the ECM results in exposure of fibrin-specific epitopes in the absence of thrombin cleavage, - dimer formation, and plasmin degradation.
A549 cell matrix-bound FBG was immunostained with those antibodies recognizing fibrinopeptides that are cleaved during FBG conversion to fibrin (Table 1). Both FPA and FPB were present in A549-matrix FBG, as shown by the intensely stained fibrillar pattern detected using antibodies against FPA (RDV3; Fig 2A) and FPB (18C6; Fig 2B). These staining patterns were similar to those detected using the fibrin (ogen)-specific MoAb J88B (Fig 1B). To determine whether fibrin-specific epitopes are exposed on matrix-bound FBG as well, immunostaining was conducted using MoAb T2G1, which recognizes the fibrin-specific epitope 15-21 (Table 1). A comparable staining pattern was shown (Fig 2D), suggesting exposure of this fibrin-specific epitope.
View larger version (71K):
[in this window]
[in a new window]
| Fig 2.
ECM of A549 lung epithelial cells stained for FBG and fibrin-specific epitopes. IL-6 + DEX-treated cells were stained with (A) MoAb RDV3 for FPA; (B) MoAb 18C6 for FPB; (C) no primary antibody; or (D) MoAb T2G1 for fibrin 15-21. The bar in (D) represents 10 µm.
|
|
To determine if matrix incorporation necessitated enzymatic cleavage of FBG, A549 cells were cultured in the presence of hirudin and aprotinin. The resultant matrix staining pattern was unaffected by the presence of these inhibitors; thus, FPA, FPB, and 15-21 epitopes are exposed (Table 2). To further confirm lack of thrombin or plasmin action on A549 cell-derived FBG, cells were metabolically labeled during the 18 hours of IL-6 + DEX induction and FBG was immunopurified from culture medium and analyzed by SDS-PAGE, followed by fluorography. FBG secreted from A549 cells showed no evidence of cleavage by thrombin (Fig 3A, lane 1) or plasmin (Fig 3B, lane 1). Furthermore, there was no evidence of the formation of - dimers or high molecular weight -polymers indicative of enzymatic cross-linking and insoluble polymer formation (Fig 3A). Subsequent exposure of these samples to thrombin resulted in the expected shift in migration of both the and chains (Fig 3A, lane 2), demonstrating that lung epithelial cell-derived FBG is sensitive to thrombin cleavage under these experimental conditions. In contrast, FBG from A549 cell-conditioned media incubated for 18 hours with plasmin did not undergo cleavage, because characteristic degradation products were absent (Fig 3B, lane 2). These results suggest that, whereas thrombin cleavage of FBG can occur under the culture conditions used, plasmin cleavage is not likely to occur due to the presence of FBS-derived plasmin inhibitors. There was no evidence of thrombin or plasmin action on 125I-labeled purified plasma FBG when incubated with 10% FBS containing medium (Fig 4C). However, 125I-plasma FBG (10 µg/mL) incubated in serum-free medium was susceptible to cleavage by these enzymes, because the addition of plasmin (Fig 4A, lane 2) or thrombin (Fig 4B, lane 2) resulted in the appearance of the expected cleavage products.
View larger version (24K):
[in this window]
[in a new window]
| Fig 3.
Susceptibility of A549 lung cell-derived FBG to thrombin and plasmin cleavage. (A) Metabolically labeled FBG in A549 conditioned media was untreated (lane 1) or treated with thrombin (lane 2) and immunopurified and the resulting fibrin(ogen) A/, B/, and chains were reduced then resolved on 7% polyacrylamide gels. (B) The untreated (lane 1) and plasmin-treated (lane 2) samples were resolved nonreduced on 8% polyacrylamide gels. The molecular weight markers (lane Mr ) in (B) are, from top to bottom, 200, 97, 68, and 46 kD. Intact FBG (340 kD) is denoted by the arrow.
|
|
View larger version (65K):
[in this window]
[in a new window]
| Fig 4.
Susceptibility of iodinated plasma FBG to thrombin and plasmin action in A549 cell medium in the presence or absence of serum. 125I-labeled FBG was added to serum-free medium and treated with plasmin (A) or thrombin (B) or to A549 conditioned 10% serum-containing medium (C). (A) represents an autoradiograph of a nonreduced, 8% polyacrylamide gel. (B) and (C) represent 7% polyacrylamide gels of reduced fibrin(ogen) polypeptide chains. (A) Lane 1, Mr denoted by arrowheads are, from top to bottom, 200, 97, 68, and 46 kD; lane 2, plasmin-cleaved 125I-FBG fragments D and E (arrows, top to bottom); lane 3, 125I-FBG plasmin-treated in the presence of 200 U/mL aprotinin; lane 4, 125I-FBG starting material. (B) Lane 1, untreated 125I-FBG A, B, and chains; lane 2, thrombin-cleaved fibrin , , and chains. (C) Lane 1, 125I-FBG in serum-free medium; lane 2, 125I-FBG + hirudin and aprotinin; lane 3, 125I-FBG + hirudin; lane 4, 125I-FBG + aprotinin.
|
|
A549 cell-derived and purified plasma FBG binds to exogenously produced ECM.
To determine whether lung epithelial cell-derived FBG could bind to exogenously produced ECM, binding of FBG to cultured HFF was studied. A549 cells were treated with IL-6 + DEX for 18 hours, and the conditioned medium was collected, overlaid onto confluent monolayers of fibroblasts, and then incubated for 72 hours at 37°C. Fibroblast cultures were also incubated for 72 hours with purified plasma FBG in HFF-conditioned media. Immunostaining of HFF using the fibrin(ogen)-specific MoAb, J88B, in the absence of permeabilization showed staining in a fibrillar pattern characteristic of ECM. Fibrin(ogen) staining in matrix was seen after incubation of HFF with both A549 cell-derived FBG (Fig 5A) and purified plasma FBG at 50 (Fig 5B), 10, and 2 µg/mL (not shown), but was absent from HFF not exposed to exogenous FBG (Fig 6G through I). The FBG staining pattern observed was exclusively extracellular in the nonpermeabilized cells, because parallel staining using antibody against the intracellular protein, -tubulin, showed no positive staining (Fig 5C).
View larger version (92K):
[in this window]
[in a new window]
| Fig 5.
Exogenously produced FBG deposition in preformed matrix of fibroblasts. A549 cell conditioned media (A) or purified plasma FBG (B) was added to confluent monolayers of HFFs grown on glass coverslips and then cultured for 3 days. The cells were fixed and stained, nonpermeabilized (A through C), with MoAb J88B for FBG (A and B) and an MoAb for -tubulin (C). Permeabilized HFFs were stained with the MoAb for -tubulin (D). The bar in (D) represents 15 µm.
|
|
View larger version (79K):
[in this window]
[in a new window]
| Fig 6.
Exposure of FBG and fibrin-specific epitopes on A549 lung cell-derived FBG and plasma FBG deposited in the ECM of fibroblasts. Immunofluorescent staining was performed using MoAbs specific for FPA (A, D, and G), FPB (B, E, and H), and fibrin 15-21 (C, F, and I). HFFs were overlaid with conditioned media from A549 cells (A through C), with complete media containing purified plasma FBG (D through F ), or with complete media with no added ligand. The bar in (I) represents 10 µm.
|
|
To ascertain if both FBG and fibrin-specific epitopes were exposed when bound to the ECM, immunostaining of HFF cultures incubated with A549 cell-derived and plasma FBG was performed with MoAbs RDV3, 18C6, and T2G1, which recognize native, fixed, denatured, and reduced FPA, FPB, and fibrin 15-21 (Table 1). Such staining indicated that both FBG- and fibrin-specific epitopes were indeed exposed (Fig 6). The presence of hirudin and aprotinin did not alter the staining pattern detected using any of these antibodies (not shown), suggesting that FBG deposition in the matrix of HFF does not involve the action of thrombin or plasmin. To further investigate the involvement of proteolytic processing during deposition of FBG into ECM, 125I-labeled purified plasma FBG (50 µg/mL) was overlaid onto HFF and incubated for 72 hours, and then monolayers were washed. Cell-associated (bound) and soluble (unbound) FBG was recovered by immunopurification and analyzed by SDS-PAGE (Fig 7). Electrophoretic mobility of reduced FBG A, B, and chains (bound and unbound) was unaltered from that of native plasma FBG, further supporting the concept that incorporation into the matrix occurs in the absence of thrombin and plasmin cleavage, as well as in the absence of - dimer or -polymer formation.
View larger version (37K):
[in this window]
[in a new window]
| Fig 7.
SDS-PAGE analysis of iodinated plasma FBG exposed to confluent monolayers of HFF for 3 days in culture. Lane 1, 125I-FBG starting material; lane 2, unbound FBG recovered from HFF media; lane 3, bound FBG recovered from cell monolayer.
|
|
To verify that FBG colocalizes with other endogenously synthesized ECM proteins, double-label immunofluorescent staining was used. HFF incubated with A549 cell-conditioned medium or plasma FBG for 72 hours were stained first with PoAbs specific for FN or laminin (LN) and then with MoAb J88B to detect FBG. Both A549 cell-derived and plasma FBG clearly colocalized with fibrillar matrix strands containing either FN or LN (Fig 8).
View larger version (79K):
[in this window]
[in a new window]
View larger version (91K):
[in this window]
[in a new window]
| Fig 8.
Colocalization of FBG with ECM constituents in HFF matrix detected by dual immunofluorescent staining. FBG from lung A549 epithelial cells or plasma was overlaid onto HFF cultures for 3 days. Matrix fibrils were detected by dual staining with anti-FN and MoAb J88B (A) or anti-LN and MoAb J88B (B) antibodies. The bar represents 20 µm.
|
|
To determine the protameric structure of these FBG fibril strands, the amount of DOC-soluble compared with DOC-insoluble FBG deposited into ECM was measured. A549-FBG from the DOC-soluble and -insoluble fractions was recovered by immunopurification and analyzed by SDS-PAGE. The fluorographs of the gels (not shown) were subjected to scanning densitometry to quantitate the relative amount of FBG in the DOC-insoluble compared with the -soluble fractions. After 2 hours of chase, the amount of DOC-insoluble FBG represented 8.6% of the A549 cell/matrix-associated fraction, which increased to 13.1% by 6 hours postlabeling and then declined to 5.4% by 24 hours. The amount of A549 cell-derived FN incorporated into DOC-insoluble material was 11.4% at 2 hours, 19.3% at 6 hours, and 8.7% at 24 hours, which closely paralleled the time course and amount of A549 cell-derived FBG incorporated into DOC-insoluble material.
A549 cell-associated FBG is cell surface or matrix-associated.
To determine the localization of A549 cell/matrix-associated FBG, cells induced with IL-6 + DEX were metabolically labeled over a short time course from 10 to 120 minutes. The washed cells were either lysed directly (cell/matrix-associated fraction) or first subjected to trypsinization to remove cell surface-bound proteins and then lysed in the standard cell lysing buffer used for immunopurification (intracellular fraction). The immunopurified FBG was analyzed by SDS-PAGE without thiol-reduction on a 6% polyacrylamide resolving gel with a 3.5% polyacrylamide stacking gel (Fig 9). Metabolically labeled FBG was not detectable in the cell/matrix-associated or trypsinized-intracellular fractions at the 10- or 20-minute time points. Intact FBG of 340 kD was first detectably cell/matrix-associated at 30 minutes, with undetectable levels of intact, labeled FBG in the corresponding intracellular pool derived from the trypsinized cells. In addition, labeled FBG was secreted into the culture media within 30 minutes (Fig 9), the time required for the secretion of newly synthesized and assembled FBG from HepG2 cells33 and A549 cells (unpublished data). As the labeling time increased, the amount of cell-associated FBG increased as well, with the majority remaining cell-surface bound and/or matrix-associated. The cell-bound FBG reached saturation between 60 and 90 minutes, with approximately 71% to 76% of the newly synthesized and secreted FBG remaining cell/matrix-associated. However, after reaching saturation of labeled FBG bound at the cell surface, the amount of FBG accumulating in the media increased. No high molecular weight aggregates were detected above FBG at 340 kD or in the stacking gel (Fig 9), consistent with the absence of high molecular weight aggregates of FBG in the DOC-soluble or -insoluble fractions analyzed by 2% agarose SDS-gel electrophoresis (not shown). In addition, no detectable intact FBG was immunopurified from the intracellular fraction of trypsinized cells, as would be expected for a rapidly secreted protein.33 Only free individual chains (A, B, or ), intermediate - and - chain complexes, and the FBG half-molecule () were detected intracellularly (Fig 9; unpublished data). Thus, all of the cell-associated FBG is in the dimeric protamer form of 340 kD composed of the characteristic A, B, and chains and not high molecular weight polymers. The FBG is extracellular, either bound to the surface of the cell and/or deposited into the ECM. Together, the data suggest that the mechanism of deposition of FBG closely parallels that of FN in A549 ECM.
View larger version (50K):
[in this window]
[in a new window]
| Fig 9.
Trypsin-sensitivity of cell/matrix-associated FBG. A549 cells were metabolically labeled with 35S-cys + 35S-met for 10 (lanes 1), 20 (lanes 2), 30 (lanes 3), 60 (lanes 4), 90 (lanes 5), and 120 (lanes 6) minutes. FBG secreted into the media was sampled at 30, 60, and 120 minutes (left panel); total FBG remaining cell-associated (middle panel) and intracellular FBG remaining after trypsinization of cell monolayers (right panel) were sampled at all time points, immunopurified, and resolved under nonreducing SDS-PAGE conditions. The position of migration of secreted and cell-bound intact FBG (disulfide-bonded A, B, and chains) is denoted at 340 kD. The intracellular intermediates of FBG were determined by two-dimensional gel electrophoresis (not shown) and are labeled accordingly.
|
|
| |
DISCUSSION |
FBG has been long regarded as serving a hemostatic role because it is converted from a soluble, plasma protein to an insoluble fibrin gel by the action of thrombin and factor XIIIa.2,4 Previous studies have identified fibrillar strands within the provisional matrix of cutaneous and vascular wounds as fibrin.34 During coagulation, additional adhesive glycoproteins from plasma become incorporated into the fibrin clot by covalent cross-linking, providing, in addition to the hemostatic plug, a scaffold for cell migration and proliferation, a reservoir for growth factors, proteases, and protease inhibitors, and a substrate for induction and modulation of cell function.34-37 Once re-epithelialization is complete or vascular integrity reestablished, fibrin is dissolved through the action of plasmin. Recently, we showed that lung epithelial cells synthesize and secrete FBG basolaterally in response to IL-6 + DEX.16,17 Furthermore, our earlier studies indicate that Pneumocystis carinii infection results in induction of FBG gene expression in lung epithelial cells in addition to its induction in hepatocytes.38 It is conceivable, therefore, that FBG synthesized at the site of wound repair or derived from plasma due to increased vascular permeability may incorporate into the provisional matrix independently of conversion to fibrin. The unexpected expression of FBG in extrahepatic cells led us to explore its role in cellular processes distinct from hemostasis. We show here deposition of lung epithelial cell FBG into extracellular matrices and its colocalization with other matrix proteins, FN and LN.
The mechanism of FBG assembly into matrix is presently not known; however, our experimental data suggest that FBG assembly in matrix may share several features with FN assembly in matrix. An accepted model of FN assembly begins with dimeric (protameric) FN binding to cell surface 51 via the RGD-containing cell adhesive region in FN repeats type III-8-10. Binding of FN to 51 results in a conformational change that enables a distinct cell surface component, the FN matrix assembly receptor, to bind the N-terminal (type I-1-5) modules of FN with high avidity. This binding facilitates disulfide cross-linking and fibril elongation, which is also facilitated by cell movement. Additional FN molecules add to the growing fibril via the homophilic binding site in the type I-9/III-1 modules (reviewed in Mosher et al39 ). Recent evidence implicates FN binding to 31 via an alternative mechanism that bypasses FN binding to 51 in matrix assembly.40 The results of this study show that the majority of the newly synthesized FBG remains cell/matrix-associated in a trypsin-sensitive fraction, a portion of which becomes incorporated over time into a detergent-insoluble matrix fraction such as the ECM constituent FN.31,32,41
A number of other similarities between FN and lung epithelial cell FBG incorporation onto matrix were found. Both lung epithelial cell-derived FBG17 and endothelial cell-derived FN are secreted basolaterally.42 This polarized secretion of FN is correlated with the localization of high-affinity FN binding sites on the basolateral but not apical face of the endothelial cell.42 Both cellular and plasma FN are known to incorporate into ECM of heterologous cell types.32,43 Similarly, lung cell-derived FBG, as well as purified plasma FBG, bind to the ECM of a heterologous cell type, namely fibroblasts. The deposition of FN into the ECM results in an extended conformer that evokes expression of latent cell binding domains in the RGDS-containing region in addition to RGDS. This conformational alteration enhances the avidity of cell binding to matrix FN over soluble FN.44 We show by a number of approaches that the deposition of FBG in the ECM occurs in the absence of plasmin degradation, thrombin cleavage, or covalent - or -polymer glutamyl-lysyl cross-linking associated with insoluble fibrin(ogen) polymer formation. Taken together, the data indicate that it is likely FBG and not fibrin that is the ECM component identified.
That the fibrin-specific epitope 15-21 is exposed in matrix-associated FBG, without demonstrable thrombin cleavage or plasmin degradation, leads to the notion that the FBG in the matrix is conformationally altered. The concept of novel binding site exposure on FBG has been previously demonstrated. FBG adsorption to various surfaces45-48 or binding to the platelet membrane glycoprotein IIb336,38,39 has been found to induce exposure of MoAb binding sites not recognized on native, soluble plasma FBG. The binding of several MoAbs is enhanced after plasmin digestion of FBG,46,48,49 suggesting that accessibility of the epitopes is due to conformational changes associated with plasmin degradation. Furthermore, the conformational changes induced by platelet IIb3-receptor binding uncover otherwise latent epitopes containing the RGDF sequence of the FBG A chain49 and residues 373-385 of the chain.48 However, the epitope, 15-21, identified by T2G1 is not exposed on surface-bound FBG.29,50 Thus, the availability of this epitope suggests that FBG interacts with the ECM in a unique fashion. Several important biologic properties have been ascribed to exposure of residues 15-42 on the fibrin neo-N-terminus as a result of thrombin cleavage, including endothelial cell spreading,8 proliferation,51 and the induction of new capillary formation in vitro.52 In addition, thrombin cleavage exposes a cryptic heparin binding domain defined by residues 15-42,53 which mediates heparin-dependent binding of soluble fibrin fragments to endothelial cells.54 The T2G1 epitope is contained within this conformationally sensitive heparin binding domain of fibrin(ogen).53 Therefore, exposure of the T2G1 binding site during assembly of FBG in matrix may involve cell surface heparan sulfate proteoglycan-dependent binding interactions.
The results of this study support the concept that there is variability in the composition of provisional matrices deposited in response to inflammation and that different cell populations may preferentially require different matrix protein configurations to induce wound healing.34 Shifts in ECM proteins may also be influenced by the cell populations that migrate in and attach to the wound site. For example, FN synthesized by resident macrophages and fibroblasts during cutaneous wound repair is the embryonic form of the protein, suggesting that this particular structure of FN may promote or enhance wound healing in this context.55 The protein content of the matrix in liver, kidneys, heart, and lungs is altered in association with various pathologies.56 Enhanced deposition of plasma FN into the subendothelial matrix can decrease the protein permeability of lung endothelial monolayers in vitro as well as the lung endothelial barriers in vivo.57
In summary, the results presented in this study provide evidence that matrix-bound FBG may possess unique structural properties. We propose that inflammation induces the synthesis and deposition of FBG in ECM. This matrix-incorporated FBG assumes a new conformation, exposing a latent epitope that may result in new adhesive properties of surface-bound FBG to promote reciprocal cell-matrix processes.
| |
FOOTNOTES |
Submitted January 21, 1997;
accepted June 3, 1997.
Supported by Public Health Service Grants No. HL50615, HL30616, and AI07362 from the National Institutes of Health (Bethesda, MD).
Address reprint requests to Patricia J. Simpson-Haidaris, PhD, Vascular Medicine, PO Box 610, 601 Elmwood Ave, Rochester, NY 14642.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
The authors thank Brian J. Rybarczyk for preparation of fibronectin-free plasma fibrinogen, Sarah O. Lawrence for radioiodination of fibrinogen, and Dr Norma B. Lerner for critical comments and suggestions regarding the manuscript.
| |
REFERENCES |
1. Koj A: Definition and classification of acute phase proteins, in Gordon A, Koj A (eds): Acute Phase Response to Injury and Infection. New York, NY, Elsevier, 1985, p 139
2.
Doolittle R:
Fibrinogen and fibrin.
Annu Rev Biochem
53:195,
1984[Medline]
[Order article via Infotrieve]
3. Millward-Sadler GH, Jezequel AM: Normal histology and ultrastructure, in Wright R, Alert KGMM, Karran S, Millward-Sadler GH (eds): Liver and Biliary Disease. Philadelphia, PA, Saunders, 1979, p 13
4. Hantgan RR, Francis CW, Marder VJ: Fibrinogen structure and physiology, in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis. Philadelphia, PA, Lippincott, 1994, p 277
5.
Dejana E,
Vergara-Dauden M,
Balconi G,
Pietra A,
Cherel G,
Donati M,
Larrieu M,
Marguerie G:
Specific binding of human fibrinogen to cultured human fibroblasts.
Eur J Biochem
139:657,
1984[Medline]
[Order article via Infotrieve]
6.
Dejana E,
Colella S,
Languino L,
Balconi G,
Corbascio G,
Marchisio P:
Fibrinogen induces adhesion, spreading, and microfilament organization of human endothelial cells in vitro.
J Cell Biol
104:1403,
1987[Abstract/Free Full Text]
7.
Liu H,
Wang D,
Liu C:
Interactions between fibrin, collagen, and endothelial cells in angiogenesis.
Adv Exp Med Biol
281:319,
1990[Medline]
[Order article via Infotrieve]
8.
Bunce LA,
Sporn LA,
Francis CW:
Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the chain.
J Clin Invest
89:842,
1992
9.
Brown L,
Lanir N,
McDonagh J,
Tognazzi K,
Dvorak A,
Dvorak H:
Fibroblast migration in fibrin gel matrices.
Am J Pathol
142:273,
1993[Abstract]
10. Varani J: The noncollagenous extracellular matrix components of pulmonary fibrosis, in Phan SH, Thrall R (eds): Pulmonary Fibrosis. New York, NY, Dekker, 1995, p 201
11.
(Simpson) Haidaris PJ,
Courtney MA:
Tissue-specific and ubiquitous expression of fibrinogen chain mRNA.
Blood Coagul Fibrinolysis
1:433,
1990[Medline]
[Order article via Infotrieve]
12.
Courtney MA,
Stoler MH,
Marder VJ,
(Simpson) Haidaris PJ:
Developmental regulation of mRNAs encoding platelet proteins in rat megakaryocytes.
Blood
77:560,
1991[Abstract/Free Full Text]
13.
(Simpson) Haidaris PJ,
Courtney MA:
Liver-specific RNA processing of the ubiquitously transcribed rat fibrinogen chain gene.
Blood
79:1218,
1992[Abstract/Free Full Text]
14.
Molmenti E,
Ziambaras T,
Permutter D:
Evidence for an acute phase response in human intestinal epithelial cells.
J Biol Chem
268:14116,
1993[Abstract/Free Full Text]
15.
Lee S,
Lee K,
Lim J:
Identification and biosynthesis of fibrinogen in human uterine cervix carcinoma cells.
Thromb Haemost
75:466,
1996[Medline]
[Order article via Infotrieve]
16.
Simpson-Haidaris PJ:
Induction of fibrinogen biosynthesis and secretion from cultured pulmonary epithelial cells.
Blood
89:873,
1997[Abstract/Free Full Text]
17.
Guadiz G,
Sporn LA,
Goss RA,
Lawrence SO,
Marder VJ,
Simpson Haidaris PJ:
Polarized secretion of fibrinogen by lung epithelial cells.
Am J Respir Cell Mol Biol
17:60,
1997[Abstract/Free Full Text]
18. Hynes R: Distribution of fibronectins in vivo, in Hynes R (ed): Fibronectins. New York, NY, Springer-Verlag, 1990, p 24
19.
Lawler J:
The structural and functional properties of thrombospondin.
Blood
67:1197,
1986[Free Full Text]
20.
Felding-Habermann B,
Cheresh D:
Vitronectin and its receptors.
Curr Opin Cell Biol
5:864,
1993[Medline]
[Order article via Infotrieve]
21.
Hoyer L:
The factor VIII complex: Structure and function.
Blood
58:1,
1981[Abstract/Free Full Text]
22. Timpl R, Aumailley M: Other basement membrane proteins and their calcium-binding potential, in Rohrbach DH, Timpl R (eds): Molecular and Cellular Aspects of Basement Membranes. New York, NY, Academic, 1993, p 211
23.
Tran H,
Tanaka A,
Litvinovich SV,
Medved LV,
Haudenschild CC,
Argraves WS:
The interaction of fibulin-1 with fibrinogen.
J Biol Chem
270:19458,
1995[Abstract/Free Full Text]
24.
Sporn LA,
Marder VJ,
Wagner DD:
von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively.
Blood
69:1531,
1987[Abstract/Free Full Text]
25.
(Simpson) Haidaris PJ,
Francis CW,
Sporn LA,
Arvan DS,
Collichio FA,
Marder VJ:
Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of chain variant polypeptides.
Blood
74:743,
1989[Abstract/Free Full Text]
26.
Odrljin TM,
Rybarczyk BJ,
Francis CW,
Lawrence SO,
Hamaguchi M,
Simpson-Haidaris PJ:
Calcium modulates plasmin cleavage of the fibrinogen D fragment chain N-terminus: Mapping of monoclonal antibody J88B to a plasmin sensitive domain of the chain.
Biochim Biophys Acta
1298:69,
1996[Medline]
[Order article via Infotrieve]
27.
Procyk R,
Kudryk B,
Callender S,
Blomback B:
Accessibility of epitopes on fibrin clots and fibrinogen gels.
Blood
77:1469,
1991[Abstract/Free Full Text]
28.
Kudryk B,
Rohoza A,
Ahadi M,
Chin J,
Weibe ME:
A monoclonal antibody with ability to distinguish between NH2 -terminal fragments derived from fibrinogen and fibrin.
Mol Immunol
20:1191,
1983[Medline]
[Order article via Infotrieve]
29.
Kudryk B,
Rohoza A,
Ahadi M,
Chin J,
Wiebe M:
Specificity of a monoclonal antibody for the NH2 -terminal region of fibrin.
Mol Immunol
21:89,
1984[Medline]
[Order article via Infotrieve]
30.
Lawrence SO,
Wright TW,
Francis CW,
Fay PJ,
(Simpson) Haidaris PJ:
Purification and functional characterization of homodimeric B-B fibrinogen from rat plasma.
Blood
82:2406,
1993[Abstract/Free Full Text]
31.
Choi MG,
Hynes RO:
Biosynthesis and processing of fibronectin in NIL.8 hamster cells.
J Biol Chem
254:12050,
1979[Abstract/Free Full Text]
32.
McKeown-Longo PJ,
Mosher DF:
Binding of plasma fibronectin to cell layers of human skin fibroblasts.
J Cell Biol
97:466,
1983[Abstract/Free Full Text]
33.
Yu S,
Sher B,
Kudryk B,
Redman C:
Fibrinogen precursors: Order of assembly of fibrinogen chains.
J Biol Chem
259:10574,
1984[Abstract/Free Full Text]
34. Clark RAF: Wound repair, in Clark RAF (ed): The Molecular and Cellular Biology of Wound Repair. New York, NY, Plenum, 1996, p 1
35.
Clark RAF,
Lanigan J,
DellaPelle P,
Manweau E,
Dvorak H,
Colvin R:
Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization.
J Invest Dermatol
70:264,
1982
36. Yamada K, Clark RAF: Provisional matrix, in Clark RAF (ed): The Molecular and Cellular Biology of Wound Repair. New York, NY, Plenum, 1996, p 51
37.
Gailit J,
Clark RAF:
Wound repair in the context of extracellular matrix.
Curr Opin Cell Biol
6:717,
1994[Medline]
[Order article via Infotrieve]
38. (Simpson) Haidaris PJ, Hui Z, Wright TW, Neroni LA, Earnest BJ, Courtney MA: Extrahepatic expression of the chain of fibrinogen during an acute phase response. Blood 80:307a, 1992 (abstr, suppl 1)
39.
Mosher DF,
Sottile J,
Wu C,
McDonald JA:
Assembly of extracellular matrix.
Curr Opin Cell Biol
4:810,
1992[Medline]
[Order article via Infotrieve]
40.
Wu C,
Chung AE,
McDonald JA:
A novel role for 31 integrins in extracellular matrix assembly.
J Cell Sci
108:2511,
1995[Abstract]
41.
McDonald JA:
Extracellular matrix assembly.
Methods Enzymol
245:518,
1994[Medline]
[Order article via Infotrieve]
42.
Kowalczyk AP,
Tolloh RH,
McKeown-Longo PJ:
Polarized secretion and localized matrix assembly sites correlate with subendothelial matrix formation.
Blood
75:2335,
1990[Abstract/Free Full Text]
43.
Allio AE,
McKeown-Longo PJ:
Extracellular matrix assembly of cell-derived and plasma-derived fibronectins by substrate attached fibroblasts.
J Cell Physiol
135:459,
1988[Medline]
[Order article via Infotrieve]
44.
Ugarova T,
Zamarron C,
Veklich Y,
Bowditch R,
Ginsberg M,
Weisel J,
Plow E:
Conformational transitions in the cell binding domain of fibronectin.
Biochemistry
34:4457,
1995[Medline]
[Order article via Infotrieve]
45.
Soria J,
Soria C,
Mirashi M,
Boucheix M,
Aurengo C,
Perrot A,
Bernadou J,
Samama M,
Rosenfeld C:
Conformational change in fibrinogen induced by adsorption to a surface.
J Colloid Interface Sci
107:204,
1985
46.
Abrams CS,
Ellison Budzynski AZ,
Shattil S:
Direct detection of activated platelets and platelet-derived microparticles in humans.
Blood
75:128,
1990[Abstract/Free Full Text]
47.
Zamarron C,
Ginsberg M,
Plow E:
Monoclonal antibodies specific for a conformationally altered state of fibrinogen.
Thromb Haemost
64:41,
1990[Medline]
[Order article via Infotrieve]
48.
Zamarron C,
Ginsberg M,
Plow E:
A receptor-induced binding site in fibrinogen elicited by its interaction with platelet membrane glycoprotein IIb-IIIa.
J Biol Chem
266:16193,
1991[Abstract/Free Full Text]
49.
Ugarova T,
Budzynski A,
Shattil S,
Ruggeri Z,
Ginsberg M,
Plow E:
Conformational changes in fibrinogen elicited by its interaction with platelet membrane glycoprotein GPIIb-IIIa.
J Biol Chem
268:21080,
1993[Abstract/Free Full Text]
50.
Courtney MA,
Bunce LA,
Neroni LA,
Simpson-Haidaris PJ:
Cloning of the complete coding sequence of rat fibrinogen B chain cDNA: Interspecies conservation of fibrin 15-42 primary structure.
Blood Coagul Fibrinolysis
5:487,
1994[Medline]
[Order article via Infotrieve]
51.
Sporn LA,
Bunce LA,
Francis CW:
Cell proliferation on fibrin: Modulation by fibrinopeptide cleavage.
Blood
86:1802,
1995[Abstract/Free Full Text]
52.
Chalupowicz DG,
Chowdhury ZA,
Bach TL,
Barsigian C,
Martinez J:
Fibrin II induces endothelial cell capillary tube formation.
J Cell Biol
130:207,
1995[Abstract/Free Full Text]
53.
Odrljin TM,
Shainoff JR,
Lawrence SO,
Simpson Haidaris PJ:
Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin chain.
Blood
88:2050,
1996[Abstract/Free Full Text]
54.
Odrljin TM,
Francis CW,
Sporn LA,
Bunce LA,
Marder VJ,
Simpson Haidaris PJ:
Heparin binding domain of fibrin mediates its binding to endothelial cells.
Arterioscler Thromb Vasc Biol
16:1544,
1996[Abstract/Free Full Text]
55.
Brown L,
Dubin D,
Lavigne L,
Logan B,
Dvorak H,
Van De Water L:
Macrophages and fibroblasts express embryonic fibronectin during cutaneous wound healing.
Am J Pathol
142:793,
1993[Abstract]
56.
Martinez-Hernandez A,
Delgado FM,
Aments PS:
The extracellular matrix in hepatic regeneration: Localization of collagen types I, III, IV, laminin, and fibronectin.
Lab Invest
64:157,
1983[Medline]
[Order article via Infotrieve]
57. Wheatley EM, McKeown-Longo PJ, Vincent PA, Saba TM: Incorporation of fibronectin into matrix decreases TNF-induced increases in endothelial monolayer permeability. Am J Physiol 265:L148, 1993
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A Masamune, K Kikuta, T Watanabe, K Satoh, M Hirota, S Hamada, and T Shimosegawa
Fibrinogen induces cytokine and collagen production in pancreatic stellate cells
Gut,
April 1, 2009;
58(4):
550 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. O. Duan and P. J. Simpson-Haidaris
Cell Type-specific Differential Induction of the Human {gamma}-Fibrinogen Promoter by Interleukin-6
J. Biol. Chem.,
May 5, 2006;
281(18):
12451 - 12457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Schubert, K. Zakikhany, G. Pietrocola, A. Meinke, P. Speziale, B. J. Eikmanns, and D. J. Reinscheid
The Fibrinogen Receptor FbsA Promotes Adherence of Streptococcus agalactiae to Human Epithelial Cells
Infect. Immun.,
November 1, 2004;
72(11):
6197 - 6205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Gutekunst, B. J. Eikmanns, and D. J. Reinscheid
The Novel Fibrinogen-Binding Protein FbsB Promotes Streptococcus agalactiae Invasion into Epithelial Cells
Infect. Immun.,
June 1, 2004;
72(6):
3495 - 3504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Rybarczyk, S. O. Lawrence, and P. J. Simpson-Haidaris
Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration
Blood,
December 1, 2003;
102(12):
4035 - 4043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. O. Duan and P. J. Simpson-Haidaris
Functional Analysis of Interleukin 6 Response Elements (IL-6REs) on the Human {gamma}-Fibrinogen Promoter: BINDING OF HEPATIC Stat3 CORRELATES NEGATIVELY WITH TRANSACTIVATION POTENTIAL OF TYPE II IL-6REs
J. Biol. Chem.,
October 17, 2003;
278(42):
41270 - 41281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Pereira, B. J. Rybarczyk, T. M. Odrljin, D. C. Hocking, J. Sottile, and P. J. Simpson-Haidaris
The incorporation of fibrinogen into extracellular matrix is dependent on active assembly of a fibronectin matrix
J. Cell Sci.,
January 2, 2002;
115(3):
609 - 617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Vaday, H. Schor, M. A. Rahat, N. Lahat, and O. Lider
Transforming growth factor-{beta} suppresses tumor necrosis factor {alpha}-induced matrix metalloproteinase-9 expression in monocytes
J. Leukoc. Biol.,
April 1, 2001;
69(4):
613 - 621.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. M. Odrljin, C. G. Haidaris, N. B. Lerner, and P. J. Simpson-Haidaris
Integrin {alpha}v{beta}3-Mediated Endocytosis of Immobilized Fibrinogen by A549 Lung Alveolar Epithelial Cells
Am. J. Respir. Cell Mol. Biol.,
January 1, 2001;
24(1):
12 - 21.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. J. Rybarczyk and P. J. Simpson-Haidaris
Fibrinogen Assembly, Secretion, and Deposition into Extracellular Matrix by MCF-7 Human Breast Carcinoma Cells
Cancer Res.,
April 1, 2000;
60(7):
2033 - 2039.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M.-D. T. Nguyen and P. J. Simpson-Haidaris
Cell Type-Specific Regulation of Fibrinogen Expression in Lung Epithelial Cells by Dexamethasone and Interleukin-1beta
Am. J. Respir. Cell Mol. Biol.,
February 1, 2000;
22(2):
209 - 217.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Bühling, A. Gerber, C. Häckel, S. Krüger, T. Köhnlein, D. Brömme, D. Reinhold, S. Ansorge, and T. Welte
Expression of Cathepsin K in Lung Epithelial Cells
Am. J. Respir. Cell Mol. Biol.,
April 1, 1999;
20(4):
612 - 619.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Guadiz, C. G. Haidaris, G. N. Maine, and P. J. Simpson-Haidaris
The Carboxyl Terminus of Pneumocystis carinii Glycoprotein A Encodes a Functional Glycosylphosphatidylinositol Signal Sequence
J. Biol. Chem.,
October 2, 1998;
273(40):
26202 - 26209.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Simpson-Haidaris, M.-A. Courtney, T. W. Wright, R. Goss, A. Harmsen, and F. Gigliotti
Induction of Fibrinogen Expression in the Lung Epithelium during Pneumocystis carinii Pneumonia
Infect. Immun.,
September 1, 1998;
66(9):
4431 - 4439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract